Skip to main content

Oby-Cap and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Oby-Cap (phentermine).

Moderate

phentermine food

Moderate Food Interaction

Using phentermine with alcohol can increase the risk of cardiovascular side effects such as increased heart rate, chest pain, or blood pressure changes. In addition, you may also be more likely to experience nervous system side effects such as dizziness, drowsiness, depression, and difficulty concentrating. You should avoid or limit the use of alcohol while being treated with phentermine. Do not use more than the recommended dose of phentermine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.

Switch to professional interaction data

Major

High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

CNS stimulants - cardiac disease

Many CNS stimulants are contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended dosages for attention deficit hyperactivity disorder; use of these agents should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias, and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam, and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Concerta (methylphenidate)." Alza (2002):
  8. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  9. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  10. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  11. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  12. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  13. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 13 references
Major

High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

CNS stimulants - hypertension

CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Concerta (methylphenidate)." Alza (2002):
  8. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  9. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  10. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  11. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  12. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  13. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 13 references

Oby-Cap drug interactions

There are 194 drug interactions with Oby-Cap (phentermine).

Oby-Cap disease interactions

There are 13 disease interactions with Oby-Cap (phentermine) which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.